RxDoctor Payments Data

Joel Doughten, MD

Geriatric Medicine · Riverside, CANPI 1740348226

Payments from drug & device makers

$595in general payments, 2019–2025

Across 24 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$312
  • Eisai Inc.$93
  • Merck$84
  • Lilly USA, LLC$71
  • Amgen$18
  • AstraZeneca$17

What the payments were for

  • Food & beverage$595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk14$312
Eisai Inc.5$93
Merck1$84
Lilly USA, LLC2$71
Amgen1$18
AstraZeneca1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$595 in reported general payments places this provider in the 70th percentile of 494 geriatric medicine providers in California.

See all geriatric medicine providers in California

Medicare billing

Part B allowed, 2024
$178,768
Medicare patients
184
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$79,704
EliquisApixaban70$67,726
TrulicityDulaglutide35$54,105
OzempicSemaglutide30$38,029
LinzessLinaclotide11$13,532
XareltoRivaroxaban15$10,796
MyrbetriqMirabegron12$9,068
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$3,425
Atorvastatin Calcium306$3,346
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen82$2,591
Memantine Hcl ErMemantine Hcl12$2,505
Tamsulosin Hcl69$1,963
Rivastigmine12$1,814
Mirtazapine96$1,728
SynthroidLevothyroxine Sodium19$1,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$71$54,10535 claims
Novo NordiskOzempic$312$38,02930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 494 geriatric medicine providers in California.

Other geriatric medicine in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →